Pacira Pharm Inc (PCRX) Stock Price, Quote & News

Company Profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld c...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 813 553 6680

Website: www.pacira.com

Address:

5401 West Kennedy Boulevard, Suite 890, Tampa, United States

GoldKing23 Jun. 11 at 3:05 PM

$PCRX Based on the one-year price targets offered by 6 analysts, the average target price for Pacira BioSciences Inc (PCRX, Financial) is $41.50 with a high estimate of $65.00

0 · Reply

GoldKing23 Jun. 11 at 1:01 PM

$PCRX https://finance.yahoo.com/news/pacira-biosciences-unveils-three-clinical-120000142.html

0 · Reply

BiopharmaWatch_com Jun. 9 at 6:19 PM

We’re tracking the biggest biotech catalysts this week on BiopharmaWatch: • Real-time FDA & PDUFA events • POA % and pipeline stage • Price and market cap trends Tickers on our radar: $OKYO $TSHA $MDGL $PCRX $NAMS Who’s on your watchlist? Tag your pick below! #Biotech #Stocks #CatalystWatch #TradingStrategy #Pharma #FDA #PDUFA #ClinicalTrials #BiotechInvesting #BiotechStocks

0 · Reply

MadMaverick Jun. 2 at 1:10 AM

$ACTU MAKING MOVES! Actuate Therapeutics just dropped topline Phase 2 results that could shake things up in metastatic pancreatic cancer 👇 🧪 The new drug combo helped patients live about 10 months, compared to just 7 months with the usual treatment — that’s a 3-month boost in survival, which is a big deal in cancer care. https://chartingdaily.com/the-future-of-oncology ✅ Statistically significant improvement ✅ Well-tolerated safety profile Communicated Disclaimer: This is not financial advice. please continue your DD and learn more about this company! $CAPR $ANAB $PCRX

0 · Reply

50bps Jun. 1 at 6:11 PM

$PCRX

0 · Reply

Night_Owl_Biotech May. 24 at 5:05 PM

FY2028 (Year 4) revenue multiples of all commercial-stage non-oncology focused bios (new since 1/1/2017) sorted low to high. 2 recent peer M&A transactions were at 5.5X FY2028 projected revenues (ITCI) and 2.6X (SWTX). $ARDX trades at the lowest FY28 multiple in this peer group but has patents expiring in FY34 so it may not be relevant but still... Others trading @ lower FY28 multiples include $PCRX $TVTX (which is down 20%+ the last week or two after the FDA accepted a filing). $ACAD just scored a major patent extension & $BHVN has an active PDUFA (but is not technically commercial-stage). Read our earlier post for cumulative 10-Year projected revenue multiples. This is not investment advice. We are merely sharing one analysis of dozens needed to assess valuation potential.

0 · Reply

Hangalvan May. 20 at 2:02 PM

$PCRX

0 · Reply

50bps May. 15 at 7:50 PM

$PCRX 👀

0 · Reply

BobbyPeruJLTC May. 12 at 4:42 PM

$PCRX give me $30 dammit

0 · Reply

JarvisFlow May. 9 at 1:00 PM

Needham has updated their rating for Pacira BioSciences ( $PCRX ) to Buy with a price target of 30.

0 · Reply

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect

Jun 12, 2025, 10:00 AM EDT - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 8 days ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect

Jun 5, 2025, 8:00 AM EDT - 11 days ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 1, 2025, 10:00 AM EDT - 15 days ago

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

May 22, 2025, 10:00 AM EDT - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out

May 20, 2025, 10:00 AM EDT - 27 days ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect

May 14, 2025, 8:00 AM EDT - 4 weeks ago

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

May 13, 2025, 10:35 AM EDT - 4 weeks ago

Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation

May 13, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out

May 11, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

May 8, 2025, 10:31 PM EDT - 5 weeks ago

Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:00 PM EDT - 5 weeks ago

Pacira BioSciences Reports First Quarter 2025 Financial Results

May 8, 2025, 10:00 AM EDT - 5 weeks ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 6, 2025, 10:00 AM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect

May 4, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation

May 2, 2025, 8:00 AM EDT - 6 weeks ago

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

May 1, 2025, 10:00 AM EDT - 6 weeks ago

Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 29, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation

Apr 29, 2025, 8:00 AM EDT - 6 weeks ago

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Apr 28, 2025, 8:00 AM EDT - 7 weeks ago

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Apr 24, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Reach Out

Apr 22, 2025, 4:01 PM EDT - 7 weeks ago

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

Apr 22, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Stockholders to Reach Out

Apr 21, 2025, 8:15 AM EDT - 2 months ago

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Apr 17, 2025, 5:00 PM EDT - 2 months ago

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Apr 9, 2025, 10:03 AM EDT - 2 months ago

Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

Apr 8, 2025, 10:45 AM EDT - 2 months ago

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Apr 7, 2025, 4:30 PM EDT - 2 months ago

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

Apr 3, 2025, 8:00 AM EDT - 2 months ago

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 14, 2025, 5:27 PM EDT - 3 months ago

Pacira BioSciences: Back On An Uptrend After Positive Developments

Mar 14, 2025, 4:05 PM EDT - 3 months ago

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

Mar 14, 2025, 8:25 AM EDT - 3 months ago

DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

Mar 13, 2025, 10:45 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

GoldKing23 Jun. 11 at 3:05 PM

$PCRX Based on the one-year price targets offered by 6 analysts, the average target price for Pacira BioSciences Inc (PCRX, Financial) is $41.50 with a high estimate of $65.00

0 · Reply

GoldKing23 Jun. 11 at 1:01 PM

$PCRX https://finance.yahoo.com/news/pacira-biosciences-unveils-three-clinical-120000142.html

0 · Reply

BiopharmaWatch_com Jun. 9 at 6:19 PM

0 · Reply

MadMaverick Jun. 2 at 1:10 AM

0 · Reply

50bps Jun. 1 at 6:11 PM

$PCRX

0 · Reply

Night_Owl_Biotech May. 24 at 5:05 PM

0 · Reply

Hangalvan May. 20 at 2:02 PM

$PCRX

0 · Reply

50bps May. 15 at 7:50 PM

$PCRX 👀

0 · Reply

BobbyPeruJLTC May. 12 at 4:42 PM

$PCRX give me $30 dammit

0 · Reply

JarvisFlow May. 9 at 1:00 PM

Needham has updated their rating for Pacira BioSciences ( $PCRX ) to Buy with a price target of 30.

0 · Reply

lecorb May. 8 at 8:28 PM

$PCRX Pacira BioSciences Non-GAAP EPS of $0.62 beats by $0.02, revenue of $168.9M misses by $6.98M

0 · Reply

BobbyPeruJLTC May. 8 at 4:37 PM

$PCRX numbers will be great. Tomorrow 30 plus

0 · Reply

BobbyPeruJLTC May. 7 at 3:33 PM

$PCRX buyback instills confidence. great earnings tomorrow and upbeat guidance and we are on a roll

0 · Reply

Thestocktraderhubzee May. 2 at 12:10 PM

$PCRX Pacira BioSciences To Present Findings From Phase 1 Study Of PCRX-201 And Its Implications For Dosing Strategy In Knee Osteoarthritis At ASGCT Annual Meeting

0 · Reply

Doozio Apr. 28 at 6:02 PM

$PCRX chop chop huckleberries… ODDS 4/7 was a MNDY 🐑 🎁 out of 🐑⏰♾️ INTA 🐒🍌🧠⏰♾️?

1 · Reply

LewisDaKat Apr. 21 at 6:55 PM

$PCRX News Article DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders https://marketwirenews.com/news-releases/doma-perpetual-supports-pacira-s-new-300-million-sha-5678303430342828.html $PCRX

0 · Reply

BobbyPeruJLTC Apr. 21 at 1:28 PM

$PCRX earnings will be better than advertised. Those institutions that removed Exparel over the past few years are accounted for. Some are coming back to use due to No pain act. ASCs liking the added indications.

0 · Reply

Rage_Against_The_Machine Apr. 21 at 12:19 PM

DOMA Perpetual (4.2% $PCRX holder) backs Pacira's $300M buyback as a catalyst for upside. With shares trading at 8x forward P/E and margins expanding, this could be the floor. Management's execution is now the key variable. Undervalued or value trap? The market's pricing in skepticism despite the math. https://www.prnewswire.com/news-releases/doma-perpetual-supports-paciras-new-300-million-share-repurchase-authorization-as-a-meaningful-step-to-enhance-value-for-shareholders-302433304.html

0 · Reply

DonCorleone77 Apr. 17 at 11:38 PM

$PCRX Pacira BioSciences authorizes $300M share repurchase program Pacira BioSciences announced its board of directors has authorized a share repurchase program of up to an aggregate of $300M of the company's common stock. The program replaces the prior authorization announced in May 2024 under the same terms and expires at the end of December 2026. The company said the authorization underscores the board's confidence in Pacira's growth strategy.

0 · Reply

Tjcmd Apr. 15 at 1:17 PM

$PCRX full effect of No Pain Act q1? q2?

1 · Reply

BobbyPeruJLTC Apr. 14 at 12:40 PM

$PCRX 14 shares premarket. Let’s see 2 bucks today. Earnings will impress

0 · Reply

NotHopeJustFacts Apr. 9 at 4:36 PM

$PCRX I said it yesterday, if you had pay attention today you will be making some $$$ closing those calls that you sold yesterday

0 · Reply

Market Cap	1.12B
Revenue (ttm)	700.97M
Net Income (ttm)	-99.56M
EPS (ttm)	N/A
PE Ratio	10.77
Forward PE	11.89
Profit Margin	-14.20%
Debt to Equity Ratio	0.38

Volume	449,729
Avg Vol	887,986
Day's Range	N/A - N/A
Shares Out	46.29M
Stochastic %K	19%
Beta	0.52
Analysts	Sell
Price Target	$34.43